Close Menu
  • Home
  • Economic News
  • Stock Market
  • Real Estate
  • Crypto
  • Investment
  • Personal Finance
  • Retirement
  • Banking

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Ethereum Dominates DeFi, Solana, Bitcoin, BSC, Tron, and Others among Top 10 

July 30, 2025

Bookkeeping Prices for Small Business: What to Expect in 2025

July 30, 2025

The 10 largest American IPOs of all time

July 30, 2025
Facebook X (Twitter) Instagram
  • Contact Us
  • Privacy Policy
  • Terms Of Service
Wednesday, July 30
Doorpickers
Facebook X (Twitter) Instagram
  • Home
  • Economic News
  • Stock Market
  • Real Estate
  • Crypto
  • Investment
  • Personal Finance
  • Retirement
  • Banking
Doorpickers
Home»Stock Market»AbbVie’s Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
Stock Market

AbbVie’s Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs

July 25, 2024No Comments1 Min Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

AbbVie’s Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs

AbbVie Inc. (NYSE:ABBV) announced its second-quarter results, with adjusted EPS at $2.65, surpassing the consensus of $2.57. Net revenues stood at $14.46 billion, exceeding the expected $14.03 billion. Sales saw an increase of 5.6% on an operational basis.

The immunology portfolio recorded $6.97 billion in sales, with notable contributions from Humira, Skyrizi, and Rinvoq. Oncology product sales reached $1.63 billion, led by Imbruvica, Venclexta, and Elahere. Neuroscience revenues were at $2.16 billion, with strong performances from Botox Therapeutic and the aesthetics portfolio.

Analysts praised AbbVie’s ability to navigate the loss of exclusivity for Humira, highlighting the company’s commercial prowess. The company raised its 2024 adjusted EPS guidance and announced the discontinuation of the Alzheimer’s drug, ABBV-916.

Despite the positive results, ABBV stock experienced a 5.14% decline to $185.26. For more stock analysis, check out Benzinga Pro.

This rewritten article is based on the original content “AbbVie’s Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs” from Benzinga.com, with all rights reserved.

AbbVies Annual beat Cancer Drugs earnings Estimates Immunology Newer profit Raises sales Strong
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

US GDP Jumps To 3.0% In Second Quarter, Trouncing Estimates And Reversing Q1 Contraction

July 30, 2025

Analyzing why Bitcoin prices hold strong despite 40K BTC sell-off

July 26, 2025

Puma Crashes Most Since 1991 After “Major Profit Warning” 

July 25, 2025
Add A Comment
Leave A Reply Cancel Reply

Top Posts

Why betting on the Trump trade is a real mistake

July 24, 20240 Views

9 Unique Things to Do in Boise, ID

October 31, 20240 Views

Survey: Top market strategists see stocks continuing to hit new all-time highs over the next 12 months

July 9, 20250 Views
Stay In Touch
  • Facebook
  • YouTube
  • TikTok
  • WhatsApp
  • Twitter
  • Instagram
Latest
Crypto

Ethereum Dominates DeFi, Solana, Bitcoin, BSC, Tron, and Others among Top 10 

July 30, 20250
Personal Finance

Bookkeeping Prices for Small Business: What to Expect in 2025

July 30, 20250
Investment

The 10 largest American IPOs of all time

July 30, 20250
Facebook X (Twitter) Instagram Pinterest
  • Contact Us
  • Privacy Policy
  • Terms Of Service
© 2025 doorpickers.com - All rights reserved

Type above and press Enter to search. Press Esc to cancel.